ITGAX and neoplasm: The discrepancy between the recent and earlier studies is likely due to XCR-1, but not Batf3 or CD11c, being specifically expressed by cDC1s; Baft3 and CD11c expression by certain non-cDC1 cells likely impacts anti-tumor immunity.